Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma

2025/10/13 by Miglino, Nicola, Toussaint, Nora C., Ring, Alexander +137
#610 - Medizin und Gesundheit #Diagnosis #Drug therapy #Erratum #Human #Male

paper · doi:10.26041/fhnw-13806

Abstract

In the version of the article initially published, the far-right column of the lower panel in Fig. 2c was missing and has now been added, as seen in Fig. 1, below. Additionally, the sentence “L.P. is a founder and shareholder of Apricot Therapeutics - a precision oncology spin-off from the University of Zurich - based on 4i drug response profiling” was missing from the Competing interests statement and has now been added. These corrections have been made to the HTML and PDF versions of the article.

Related

• Correction: Learning from the “tail end” of de-implementation: the case of chemical castration for localized prostate cancer (Implementation Science Communications, (2021), 2, 1, (124), 10.1186/s43058-021-00224-8)
• [Erratum] Long non-coding RNA KCNQ1OT1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504
• Correction: Rapid Diagnosis of Lung Tumors, a Feasability Study Using Maldi-Tof Mass Spectrometry
• EXPRESSION OF CONCERN: Intelligent TAT‐Coupled Anti‐HER2 Immunoliposomes Knock Downed MDR1 to Produce Chemosensitize Phenotype of Multidrug Resistant Carcinoma
• Rational Molecular Editing: A New Paradigm in Drug Discovery